“LSN dramatically reduces the equipment costs for hospitals,” said Bob Jacobus, CEO, AI Metrics.
BIRMINGHAM, Ala. (PRWEB) December 19, 2022
AI Metrics, an early stage radiology software company, announced that the company’s recently published research in the American Journal of Roentgenology (AJR) has been awarded the Best of AJR in the Gastrointestinal Imaging section for 2022.
AI Metrics co-founder Dr. Andrew Smith developed an innovative digital biomarker for accurately detecting and staging liver fibrosis and decompensation, termed Liver Surface Nodularity (LSN), and published the research along with company co-founders Paige Severino and Bob Jacobus. Additional co-authors of the paper included industry partners and researchers from Duke University, UAB, The Cleveland Clinic, University of Wisconsin, Mayo Clinic and UC San Diego.
The article, entitled “Multi-institutional Evaluation of the Liver Surface Nodularity Score on CT for Staging Liver Fibrosis and Predicting Liver-Related Events in Patients with Hepatitis C,” was nominated by the AJR editorial board and will be included in the February 2023 issue of the AJR.
AI Metrics commercialized Dr. Smith’s research by developing a software module that enables patient evaluation from standard CT scans. Prior to this innovation, physician options for such liver analysis were limited to invasive liver biopsies or complex evaluations using specially outfitted MRI equipment.
“LSN dramatically reduces the equipment costs for hospitals,” said Bob Jacobus, CEO, AI Metrics. “And, since LSN analysis eliminates the need for patient fasting, this clinical biomarker will reduce patient cancellations and increase equipment utilization. This is just one example of the impact of digital biomarkers on reducing healthcare costs.”
About AI Metrics
AI Metrics was founded to help radiologists be more productive when evaluating patients with advanced cancers and chronic liver disease. In addition to the company’s LSN software, its advanced cancer analysis system helps radiologists evaluate patients twice as fast, with increased accuracy, decreased variation in care, and clearer reports for oncologists and their patients. The company holds 20 U.S. and international patents, and its technology is currently in use at 10 healthcare institutions globally.